Hospira Inc

Hospira — Investor Day (September 2011)

131 slides from Hospira's investor day presentation, Sep 7, 2011

  1. Slide 1: Hospira 2011 Investor Day

    1 World’s Leading Provider of Injectable Drugs and Infusion Technologies Hospira 2011 Investor Day September 7, 2011 Lake Forest, Illinois

  2. Slide 2: Agenda

    Agenda Break Sumant Ramachandra & Anil D’Souza Pipeline and Products Event Adjourns; Shuttle Departs 3:00 p.m. Mike Ball & Presenters Q&A Tom Werner Financial Strategy Jim Hardy Operational Excellence . Lunch with Hospira Management 12:00 p.m. Tim Oldham & Ron Squarer - APAC Svend Andersen & Paul Gr

  3. Slide 3: Housekeeping Items

    Housekeeping Items Handouts Electronics Restrooms Q&A Transportation Safety

  4. Slide 4: Safe Harbor

    Safe Harbor This event contains forward-looking statements within the meaning of the federal securities laws. Hospira intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the federal securities laws. In some cases, you can identify th

  5. Slide 5: Mike Ball, Chief Executive Officer

    1 World’s Leading Provider of Injectable Drugs and Infusion Technologies Mike Ball Chief Executive Officer

  6. Slide 6: Investor Day Objectives

    2 Investor Day Objectives Deepen relationship with management Discuss key growth drivers and strategy Provide 2016 financial goals Answer questions

  7. Slide 7: What Differentiates Hospira (Why I Came)

    3 What Differentiates Hospira (Why I Came) US-centric company with tremendous international opportunities Channel strength and share gives customer-centric opportunity for differentiation High probability of success and short-cycle-time generic R&D model with good pipeline Barriers to entry Company

  8. Slide 8: Around the World in Days

    4 Around the World in 150 Days Toronto 4/14, 7/12 Wisconsin 4/6 Los Angeles 6/9 NYC 5/4 Boulder 5/5 San Diego 5/19 Chicago 3/30 Rocky Mount 8/12 Leamington Spa 7/5, 6/6 Paris 7/7 Singapore 5/29 Tokyo 6/3 Osaka 6/2 Seoul 6/30 Melbourne 6/29 Ahmedabad 8/25 Chennai 8/23 Vizag 8/20

  9. Slide 9: My Learnings

    5 My Learnings Past 150 days Hospira’s biggest opportunities and challenges Key areas of focus Strength of management team

  10. Slide 10: Key Questions We Will Address Today

    6 Key Questions We Will Address Today With the large Paragraph IVs launched, what kind of growth can we expect to see from Hospira’s core SIP business? How can Hospira profitably compete in biosimilars? How does Hospira accelerate growth outside the US and what is the margin potential in these regio

  11. Slide 11: Hospira's Investment Thesis

    7 Hospira’s Investment Thesis We are riding the wave of healthcare megatrends 1 We are best positioned to capture share 3 The global market opportunity for Hospira is huge 2

  12. Slide 12: Healthcare Megatrends Play to Our Strengths

    8 8 Healthcare Megatrends Play to Our Strengths Aging population Rising costs Increased access To reduce costs medication errors infection To improve patient safety caregiver safety productivity Improved outcomes Trends Our Strengths

  13. Slide 13: Aging Populations: Healthcare Costs Growing

    0 10 20 30 40 50 60 70 80 90 95+ 0 5 10 15 20 9 1. Aging Populations: Average Expenditures Growing EU Healthcare Costs for Patients 65+ are Increasing Significantly Average per Capita Expenditure in EU as Percentage of Per Capita GDP (%) Age (Years) And the US faces a similar situation with aging Ba

  14. Slide 14: Healthcare Spend: Burdening Global Economy

    10 2. Healthcare Spend: Burdening Global Economy Source: PwC Health Research Institute 2010. US Healthcare Spend as a % of GDP is Increasing Significantly US Healthcare Expenditures as a % of GDP 0% 5% 10% 15% 20% 25% 2000 2010 2020

  15. Slide 15: Increased Access: Emerging Markets

    11 3. Increased Access: Emerging Markets Source: PwC Health Research Institute 2010. % Growth in GDP, Health Spending 2010-2020 GDP growth Health spending growth As emerging countries’ standards of living grow, demand for healthcare is on the increase This decade will see significant upward mobility

  16. Slide 16: Need to Improve Outcomes: Serious Hospital Issue

    12 4. Need to Improve Outcomes: Serious Hospital Issue Number of people harmed each year by medication errors in US1 1.5M Excess healthcare costs incurred by hospital-acquired infections (HAI) in US a year3 ~ $30B Estimated economic burden caused by medication errors in US every year2 $77B Institute

  17. Slide 17: Hospira's Investment Thesis

    13 We are riding the wave of healthcare megatrends 1 The global market opportunity for Hospira is huge 2 We are best positioned to capture share 3 Hospira’s Investment Thesis

  18. Slide 18: Long Growth Runway: Multiple Growth Drivers

    14 Long Growth Runway for Hospira – Multiple Growth Drivers 2. Products losing market exclusivity 1. Existing SIP market growth 3. Medication Management growth 5. Biosimilars 4. Global portfolio expansion 14

  19. Slide 19: Tremendous Opportunity in Markets Outside the US

    16 Tremendous Opportunity in Markets Outside the US Source: Hospira, July 2011. Hospira SIP Marketed Molecules by Country Number of On-market Generic Molecules 0 140 20 40 60 80 100 120

  20. Slide 20: Tremendous Opportunity in Markets Outside the US

    17 Tremendous Opportunity in Markets Outside the US Source: Hospira, July 2011. Hospira SIP Marketed Molecules by Country Number of On-market Generic Molecules 0 140 20 40 60 80 100 120 Spain +59 Germany +68 Italy +42 UK +46 France +66 Additional molecules +

  21. Slide 21: Increase Available Market by Qualifying Products in More Countries

    18 We Can Increase the Available Market by Qualifying Our On-Market Products in More Countries Hospira +$5B $12B Additional opportunity for existing products in our current footprint: +$5B Source: IMS 2010; Hospira analysis. Opportunity represented by launching Hospira on-market generic injectable p

  22. Slide 22: Tapping into the Emerging Market Opportunity

    20 And by Tapping into the Emerging Market Opportunity Hospira +$5B +$5B +$6B $12B Emerging market opportunity: +$5B Source: IMS 2010; Hospira analysis; emerging market data derived from Datamonitor report on injectables for BRIC countries and IMS for rest of world.

  23. Slide 23: Opportunity to Increase Participation in Generic Injectable Market

    21 Hospira has Tremendous Opportunity to Increase Our Participation in the Generic Injectable Market Current Hospira Hospira’s potential share +$5B +$5B +$6B $12B Total market size: $28B Additional opportunity for existing products in our current footprint: +$5B Additional generic opportunity in exi

  24. Slide 24: Generics Remain Underutilized Around the Globe

    22 Generics Remain Underutilized Around the Globe Megatrends will drive increased generic utilization 0 20 40 60 80 100 Source: IMS Health, Midas, Market segmentation, June 2009; Prescription-only generics. % Generic Market Share (units) U.S. Canada Germany Poland UK Brazil Czech France Turkey Austr

  25. Slide 25: Generics Remain Underutilized Around the Globe

    23 Generics Remain Underutilized Around the Globe Megatrends will drive increased generic utilization 0 20 40 60 80 100 Generic penetration opportunity: +$2B Source: IMS Health, Midas, Market segmentation, June 2009; Prescription-only generics. % Generic Market Share (units)

  26. Slide 26: Global SIP Objective

    24 Global SIP Objective #1 generic injectable provider in every major market we serve

  27. Slide 27: Biosimilars Present Another Growth Opportunity

    25 Biosimilars Present Another Compelling Growth Opportunity Source: Hospira analysis of Datamonitor IMS data, Dec. 2010; excludes vaccines. Global Biologics Total $116B; Growing at 6.3% Per Year Europe $29.9B Japan $8.5B US $53.1B Rest of World $24.6B

  28. Slide 28: Focusing on Key Biologic Therapeutic Areas

    26 Hospira is Focusing on Key Biologic Therapeutic Areas Disease Group1 2010 Sales2 ($B) Immunology & Inflammation $28.8 Oncology $25.5 Diabetes $15.6 Multiple Sclerosis $9.6 Erythropoiesis-Stimulating Agent $8.5 Others $27.7 Industry Biologics Opportunity by Therapeutic Area Source: Hospira analysi

  29. Slide 29: Medication Management Opportunities With IV Clinical Integration

    27 Medication Management Also Has Opportunities With IV Clinical Integration as the Future of MMS IV Clinical Integration forecast to grow US MMS market by ~$400M by 2016 IV Clinical Integration (IVCI): a closed-loop system linking the IV pump, physician order, patient and patient record Future diff

  30. Slide 30: Emerging Markets Opportunities for Medication Management

    28 Current Situation And Emerging Markets Offer Opportunities for Medication Management Large number of gravity infusions in developing world Examples: China: 1.5B Brazil: 151M Gravity infusions do not meet infusion pump precision levels Opportunity Heavy reliance on gravity infusions results in nee

  31. Slide 31: Hospira's Investment Thesis

    29 Hospira’s Investment Thesis We are riding the wave of healthcare megatrends 1 The global market opportunity for Hospira is huge 2 We are best positioned to capture share 3

  32. Slide 32: Channel Strength: Grow Generic Injectable Leadership Position

    30 Source: IMS 2010; Hospira analysis. Market share in units represents the market of genericized products in which Hospira participates. Global Generic Injectable Market (Units) Market of generic injectables in which Hospira participates Invest R&D dollars to expand global portfolio Differentiate t

  33. Slide 33: Channel Strength: Drive Medication Management Penetration

    31 Source: 2010 MDI, IMS Hospital Supply Index, Millennium Research Group, other syndicated and company reports; internal analysis. Market includes hospital and alternate site channels and BRIC countries. MMS (Medication Management Systems) is part of Medication Management, which also includes gravi

  34. Slide 34: End-to-End Solution Increases Utilization

    32 Offering an End-to-End Solution Increases Utilization +6% revenue +20% revenue +20% Total additional revenue lift to SIP & differentiated delivery revenue when selling Hospira solutions and pumps Source: Hospira regression analysis. SIP alone represents an account that does not purchase Hospira s

  35. Slide 35: World's Leading Provider of Injectable Drugs and Infusion Technologies

    33 33 We are the World’s Leading Provider of Injectable Drugs and Infusion Technologies SIP MMS Biosimilars Consumables Solutions US Global US Global OUS Global US OUS Hospira Fresenius Teva Sandoz Baxter CareFusion B. Braun ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü ü Hospi

  36. Slide 36: Leverage Our Infrastructure

    34 Leverage Our Infrastructure Increase volume across the enterprise Improve efficiency through LEAN manufacturing Ensure high-quality, low-cost manufacturing Leveraging Infrastructure not only Supports Revenue Growth but also Drives Margin Expansion

  37. Slide 37: Vizag, India Facility

    35 Approximately a 1.1M square-foot facility Capability for both terminal sterilization and aseptic processing More than 50 molecules across vials, Carpuject™ and ampoules Total capacity of over 500M vials per year Vizag, India Facility: Building Significant Capacity for Future Growth

  38. Slide 38: Employee Engagement

    Employee Engagement Strategy crystal clear and understood Aligned Team - not silos Nimble - quick decision making Accountability and responsibility Relentless execution Results oriented Laser focus on the MAIN THING

  39. Slide 39: Vision for 2015+ Across Three Time Horizons

    37 Focus on high-quality manufacturing Remediate MMS Invest in global SIP International penetration with tuck-in acquisitions Continued biosimilar launches OUS New product launches Recapture US share for select molecules Enhance customer-centricity We are Accomplishing our Vision for 2015+ Across Th

  40. Slide 40: Our Mandate is Clear

    38 Our Mandate is Clear Hospira is the World’s Leading Provider of Injectable Drugs and Infusion Technologies

  41. Slide 41: Portfolio of Products

    1 Portfolio of Products Sumant Ramachandra and Anil D’Souza

  42. Slide 42: Agenda

    2 Agenda Small-molecule generics Small-molecule pipeline Biosimilars Proprietary pharma Medication management and IV clinical integration Contract manufacturing

  43. Slide 43: Multi-Faceted Strategy to Grow Small-Molecule Generic Injectables

    3 A Multi-Faceted Strategy to Grow Our Small-Molecule Generic Injectables Portfolio 1. Originator products losing market exclusivity 2. IP strategies 3. Portfolio expansion 4. Differentiated delivery systems

  44. Slide 44: Originator Products Losing Market Exclusivity

    4 1. Originator Products Losing Market Exclusivity: Market Landscape Remains Attractive * Local Market Value (LMV) refers to IMS July 2010 moving annual total (MAT) sales of equivalent products already being sold in market, whether patented or generic. LMV is not a forecast of Hospira’s expected net

  45. Slide 45: Leveraging IP Strategies to Maximize Return and Minimize Risk

    5 2. Leveraging IP Strategies to Maximize Return and Minimize Risk IP Strategy Upside Downside Hospira Success Litigation leader Hospira takes active steps, including litigation to establish a first-to-market position Potential duopoly position with the originator Hospira assumes all the litigation

  46. Slide 46: Portfolio Expansion

    6 3. Portfolio Expansion: Developing Products to Increase Participation in the Generic Injectable Market Current Hospira Hospira’s potential share +$5B +$5B +$6B $12B Total market size: $28B Additional opportunity for existing products in our current footprint: +$5B Additional generic opportunity in

  47. Slide 47: Differentiated Delivery Systems

    7 4. Differentiated Delivery Systems: Support a Competitive Leadership Position Hospira is constantly evaluating unmet customer needs to enhance and expand its differentiated drug delivery portfolio ADD- Vantage™ VisIV™ Flex Bags iSecure™ Syringe Patient Safety Caregiver Safety Workflow Productivity

  48. Slide 48: Agenda

    8 Agenda Small-molecule generics Small-molecule pipeline Biosimilars Proprietary pharma Medication management and IV clinical integration Contract manufacturing

  49. Slide 49: Pipeline Update: Small-Molecule Injectables

    9 Pipeline Update: Small-Molecule Injectables PREVIOUS Reporting Methodology 20 25 Submitted for regulatory approval LMV*: $3.6B 45 Molecules with LMV* of $11B * LMV (local market value) refers to IMS 2010 sales of equivalent products already being sold in market, whether patented or generic. LMV is

  50. Slide 50: Pipeline Update: New Reporting Methodology

    10 * LMV (local market value) refers to IMS 2010 sales of equivalent products already being sold in market, whether patented or generic. LMV is not a forecast of Hospira’s expected net sales. 55 32 28 APAC EMEA Americas Includes additional countries beyond the previous methodology Better reflects Ho

  51. Slide 51: Timing of Pipeline Launches

    11 Timing of Pipeline Launches: 71% of Hospira’s Overall $16B LMV* Pipeline Launching Over the Next Five Years Small-Molecule Generic Pipeline Based Upon Planned Launch Year Source: IMS 2010, Hospira analysis. 2H 2011 2013 2014 2015 2016 2012 2017+ (Local Market Value*) *Local market value refers to

  52. Slide 52: Pipeline of New-to-Country Launches

    12 Hospira’s Pipeline of New-to-Country Launches with LMV* of $16B Currently Targeting 623 New Country Launches APAC 77 Americas 71 EMEA 475 *Local market value refers to 2010 annual sales of equivalent products already being sold in the market, whether patented or generic. Local market value is not

  53. Slide 53: Pipeline Focused on Key Therapeutic Areas

    13 The Pipeline is Focused on Key Therapeutic Areas * LMV (local market value) refers to 2010 annual sales of equivalent products already being sold in the market, whether patented or generic. LMV is not a forecast of Hospira’s expected net sales. Source: IMS 2010; Hospira analysis. Hospira’s small

  54. Slide 54: Agenda

    14 Agenda Small-molecule generics Small-molecule pipeline Biosimilars Proprietary pharma Medication management and IV clinical integration Contract manufacturing

  55. Slide 55: Well Positioned for Emerging Profile of Biosimilars

    15 Hospira Well Positioned to Deal with Emerging Profile of Biosimilars Source: FTC Report June 2009; Hospira internal analysis Probability of success Cost Time Product op. profit margins Barriers to entry Point of differentiation Competitors Decision makers Marketing investment Pricing Biosimilars

  56. Slide 56: Capabilities to Develop, Manufacture and Commercialize Biosimilars

    16 Hospira has the Capabilities to Develop, Manufacture and Commercialize Biosimilars Research and Bioprocess Microbial and mammalian cell line development EMA approved cell culture processes mAb process development and scale-up Pegylation process development and scale-up Clinical, Regulatory and IP

  57. Slide 57: Global Biosimilar Legal and Regulatory Environment

    17 The Global Biosimiliar Legal and Regulatory Environment is Evolving 2009 2011 2000-2004 2008 Canada Australia Europe Japan United States (established legal pathway) Europe (mAb draft) 2010 Biosimilars have Advanced in All Key Regulated Markets FDA and EMA are exploring areas for collaboration in

  58. Slide 58: Commercial Inroads with Retacrit and Nivestim

    18 Hospira has Already Made Significant Commercial Inroads with Retacrit™ and Nivestim™ Retacrit (short-acting EPO): EU approved in December 2007 Expanding to Central and Eastern Europe Retacrit is the #1 EPO biosimilar in EMEA Biosimilars have 18% of the EU EPO market Retacrit ~50% EPO Biosimilar M

  59. Slide 59: Preparing for Market Formation in US

    19 We are Preparing for Market Formation in US Key decision makers in the US perceive biosimilars to be more similar to a brand than to a generic, at least in the initial years Biosimilars will require a certain level of clinical detailing to decision makers; activities to address the range of stake

  60. Slide 60: One of the Industry's Largest Biosimilar Pipelines

    20 Hospira has One of the Industry’s Largest Biosimilar Pipelines * LMV (local market value) refers to 2010 annual sales of equivalent products already being sold in the market, whether patented or generic. LMV is not a forecast of Hospira’s expected net sales. LMV Source: IMS 2010; Hospira, Celltri

  61. Slide 61: Achieving Significant R&D Milestones

    21 Achieving Significant R&D Milestones EPO Successfully completed Phase I US Phase III starts in Q4 2011 Filgrastim Approval in Australia Pre-IND meeting with FDA Improved label to include 7 day out of fridge Pegfilgrastim Optimized process and formulation mAb 1 Global clinical pathway Phase I star

  62. Slide 62: Capturing the Biosimilar Opportunity

    22 Hospira is Capturing the Biosimilar Opportunity with Retacrit™ and Nivestim™ Hospira is planning to commercialize our biosimilars Retacrit and/or Nivestim in up to 49 countries

  63. Slide 63: Pipeline Will Allow Us to Market Biosimilars Across the Globe

    24 Hospira’s Pipeline Will Allow Us to Market Biosimilars Across the Globe

  64. Slide 64: Agenda

    25 Agenda Small-molecule generics Small-molecule pipeline Biosimilars Proprietary pharma Medication management and IV clinical integration Contract manufacturing

  65. Slide 65: Precedex Cornerstone of Proprietary Pharma Strategy

    26 Precedex™ Forms the Cornerstone of Hospira’s Proprietary Pharma Strategy Established Precedex as a leading injectable sedation agent in US Additional submissions forthcoming to support long-term indication (>24 hours) and pediatric use Exploring opportunities to extend franchise beyond current pa

  66. Slide 66: Posidur and Dyloject Leverage Precedex Platform

    27 Posidur™ and Dyloject™ Will Leverage Our Precedex™ Platform Late-stage pipeline products designed to capitalize on acute-care channel strength built over past decade with Precedex Experienced US sales force with strong physician relationships and direct coverage across top-quartile hospitals Posi

  67. Slide 67: Agenda

    28 Agenda Small-molecule generics Small-molecule pipeline Biosimilars Proprietary pharma Medication management and IV clinical integration Contract manufacturing

  68. Slide 68: Global Leader in Medication Management Systems

    29 29 Global Devices (MMS) (Units) Global MMS market value (2010): $2.8B Hospira’s MMS portfolio (2010): $0.6B ~21% market share ($) Growing OUS portfolio Serve both hospital and alternate site channels Hospira is a Global Leader in Medication Management Systems with Room to Grow Hospira holds a lea

  69. Slide 69: MMS is Key to Our Portfolio Strategy

    30 And MMS is Key to Our Portfolio Strategy MMS is synergistic with the rest of our portfolio Differentiates us versus other manufacturers of generic SIP Each pump sale associated with greater than $1,700 in annual pull-through revenue will grow further as IV clinical integration increases software

  70. Slide 70: IV Clinical Integration: Next-Wave Opportunity

    31 IV Clinical Integration (IVCI): Next-Wave Opportunity Facilitates seamless communication between hospital EMR systems, pumps and other devices Connects the pump, order, patient and record Customer demand is building Supporting technology in place in most hospitals IVCI Supports Improved Patient O

  71. Slide 71: Clinical Integration: Early Results are Promising

    32 Clinical Integration: Early Results are Promising 60% reduction in reported heparin administration errors1 Safer Nursing time to program pumps reduced 25%1 Efficient $6M-$10M saved annually2 by preventing adverse drug events3 Fiscal R Paoletti and A Prusch, Advancing Smart Pump Safety with IV Int

  72. Slide 72: TheraDoc Addressing Significant Customer Need

    33 TheraDoc™ Addressing Significant Customer Need Key Market Trends / Plans Real-time clinical surveillance with embedded knowledge to improve clinical workflow and decisions Increase in regulatory pressures on quality / performance metrics alerting / intervention tools demanded Increase in global t

  73. Slide 73: Emerging Markets Offer Opportunities for Medication Management

    34 Current Situation Emerging Markets Offer Opportunities for Medication Management Large number of gravity infusions in developing world Examples: China: 1.5B Brazil: 151M Gravity infusions do not meet infusion pump precision levels Opportunity Heavy reliance on gravity infusions results in need fo

  74. Slide 74: Agenda

    35 Agenda Small-molecule generics Small-molecule pipeline Biosimilars Proprietary pharma Medication management and IV clinical integration Contract manufacturing

  75. Slide 75: Contract Manufacturing - One2One

    36 Contract Manufacturing – Hospira’s One2One™ A good business for Hospira with significant growth opportunities Hospira’s 2011-2016 projected CAGR: low teens, above market growth Provides cost-effective manufacturing solutions to global pharma and biotech companies Leveraging Hospira’s strong reput

  76. Slide 76: In Summary: Driving Growth Through Focused Product Strategies

    37 IN SUMMARY We are Driving Growth Through Our Focused Product Strategies The market opportunity for generic injectables is large We are well positioned with our multi-pronged strategy to capture share We are at the forefront of biosimilars and preparing for market formation in the US We are drivin

  77. Slide 77: Hospira - Regional Strategy

    1 Hospira – Regional Strategy September 7, 2011

  78. Slide 78: Agenda

    2 Agenda Americas EMEA APAC

  79. Slide 79: Americas At-A-Glance

    Americas At-A-Glance 3 Growth Drivers SIP portfolio expansion Biosimilars Dyloject™ Posidur™ Differentiated delivery systems Clinical integration in MMS Key Products Docetaxel Precedex™ Symbiq™ Heparin Vancomycin Plum A+™ Hydromorphone ADD-Vantage™ MedNet™ Meropenem iSecure™ VisIV™ 2010 Sales: $3.1B

  80. Slide 80: Strategy: US

    4 Strategy: US Expand #1 generic injectables leadership position Maximize new product launches leveraging differentiated offerings Target on-market generics not in current Hospira portfolio Generic Injectables Medication Management Clinical Integration Biosimilars Proprietary Reintroduce Symbiq™ to

  81. Slide 81: Strategy: Canada & Latin America

    5 Strategy: Canada & Latin America Extend SIP leadership with enhanced pipeline launches and differentiated delivery systems Establish MMS technology leadership position Drive Precedex™ growth, leveraging enhanced sales and marketing Canada LATAM Biosimilars Proprietary Other key Initiatives Grow Br

  82. Slide 82: Brazil: Unlocking Potential Growth Opportunities

    6 Brazil: Unlocking Potential Growth Opportunities Building on our leadership in-country clinical sales force Expanding SIP through local manufacturing footprint Capitalizing on opportunities for generic injectables and biosimilars Leveraging Brazil to drive future growth in Latin America markets Ou

  83. Slide 83: Agenda

    7 Agenda Americas EMEA APAC

  84. Slide 84: EMEA At-A-Glance

    8 EMEA At-A-Glance GemStar™ Oxaliplatin Meropenem Key Products Docetaxel Retacrit™ Heparin Paclitaxel Nivestim™ Plum A+™ Irinotecan Gemcitabine CLAVE™ Growth Drivers SIP portfolio expansion Biosimilars MMS in selected markets Emerging markets Cross selling 2010 Sales: $0.5B 2011-2016 Sales CAGR (E):

  85. Slide 85: Strategy: EMEA

    9 Strategy: EMEA Expand on-market Hospira products into additional Hospira markets Apply pricing analytics with integrated supply chain Prepare for second-generation US differentiated products Generic Injectables Biosimilars MMS Infrastructure Cross Selling Opportunities Leverage product positions i

  86. Slide 86: EMEA: Portfolio Expansion

    10 EMEA: Portfolio Expansion Leverage base: Leverage established positions in countries such as Spain, France, Italy and UK New dedicated business unit structure Drive Go-To-Market Program, which is linked to new business unit structure Portfolio expansion Introduce on-market Hospira products to add

  87. Slide 87: Agenda

    11 Agenda Americas EMEA APAC

  88. Slide 88: APAC At-A-Glance

    APAC At-A-Glance 12 Growth Drivers Precedex Branded pharmaceuticals Portfolio and channel expansion, especially Japan and China 2010 Sales: $0.3B 5-year Sales CAGR (E): Direct presence: 9 Key markets: Australia, Japan, China, Korea Distributor markets: 9 Key Products Precedex™ Nivestim™ Norepinephri

  89. Slide 89: Strategy: APAC

    13 Strategy: APAC Extend #1 SIP position in Australia Leverage clinical selling capabilities to maximize branded pharmaceutical and biosimilar products Create new value for customers by leveraging “vial to vein” portfolio Australia Japan & Korea China Maximize Precedex™ (sales effectiveness and life

  90. Slide 90: Building Expertise in Unique Markets - Japan

    14 Building Expertise in Unique Markets – Japan Large market 2nd largest healthcare market Aging population 40% over 65 years by 2050 vs. 23% in 2010 Healthcare funding gap $190B by 2020 Significant inefficiencies opportunity generic penetration 21% average length of hospital stay 14+ days technolog

  91. Slide 91: Building Expertise in Unique Markets - China

    15 Building Expertise in Unique Markets – China Fastest growing large injectables market in the world Key driver: Unique emphasis on IV treatment high unmet needs China Injectable Prescription Market ($B)1 33% CAGR 22-24% CAGR 1 Ex manufacturer $65-$75B $21B $9B 2006 2009 2015

  92. Slide 92: Operational Excellence

    1 Operational Excellence Jim Hardy

  93. Slide 93: Agenda

    2 2 2 Quality improvements Capacity to serve today Inventory as a patch Remediation update Investing in the future Agenda Summary

  94. Slide 94: Quality is Key to Supporting Our Growth

    3 3 3 Quality is Key to Supporting Our Growth Ensures regulatory compliance Drives customer satisfaction Drives efficiencies in development of global products Growth Focus on Quality Broad product portfolio in global markets

  95. Slide 95: Repositioning Hospira for Operational Excellence

    4 4 4 2004-2006 2007-2010 2011+ Inherited disparate systems Aged facilities New platforms for growth Standardization First-pass quality New leadership Repositioning Hospira for Operational Excellence Spin-off and Transition Acquisition and Integration Operational Excellence

  96. Slide 96: Making Progress in Our Quality Journey

    5 5 Making Progress in Our Quality Journey 2010 2011 2012 2013 and beyond Phase 1: Standardization Global quality systems Phase 2: Driving Value In Elevating customer service levels Improved predictive quality processes Phase 3: Staying in Front Continuous improvement culture

  97. Slide 97: Agenda

    6 6 6 Quality improvements Capacity to serve today Inventory as a patch Remediation update Investing in the future Agenda Summary

  98. Slide 98: Customer Service Levels Affected by 2010 Challenges

    7 7 7 Customer Service Levels Affected by 2010 Challenges Global Customer Service Levels 2009 2010 2011 Customer service levels are measured as products ordered that are filled complete and on time. 80% 84% 88% 92% 96% 100% Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec

  99. Slide 99: Addressing the Industry Capacity Challenges

    8 8 8 Addressing the Industry Capacity Challenges Competitors going off-market Tightened regulatory expectations Commodity / API supply issues Slower cycle times Aged asset base

  100. Slide 100: Investing in Process, Tools and Equipment

    9 9 9 Investing in Process, Tools and Equipment Installed five additional lyophilizers Installed two additional flip-top vial fillers Installed one cartridge-syringe filler Integrated business planning process Statistical safety stock Driving LEAN capabilities Recent Capacity Investments Getting Mor

  101. Slide 101: Agenda

    10 10 10 Quality improvements Capacity to serve today Inventory as a patch Remediation update Investing in the future Agenda Summary

  102. Slide 102: Inventory was a Quick Fix for Service Levels

    11 11 11 Inventory was a Quick Fix for Service Levels Inventory / Global Customer Service Levels 2009 2010 2011 ($ thousands) Customer Service Levels Inventory Inventory Customer Service Levels $600 $700 $800 $900 $1,000 $1,100 $1,200 Jun Sep Dec Mar Jun Sep Dec Mar Jun Sep Dec 80% 84% 88% 92% 96% 1

  103. Slide 103: New Capabilities Reduce Inventory Without Risk to Service

    12 12 New Capabilities will Enable Us to Reduce Inventory Without Risk to Customer Service Statistical safety stock pilot Improved demand planning Enhanced integrated business planning Increased lab capacity 2011 Full implementation of statistical safety stock Vendor managed inventory 2012 Inventory

  104. Slide 104: Agenda

    13 13 13 Quality improvements Capacity to serve today Inventory as a patch Remediation update Investing in the future Agenda Summary

  105. Slide 105: Warning Letter Update: Rocky Mount

    14 Warning Letter Update: Rocky Mount Subsequent to the June 2011 inspection, the FDA completed another inspection in August, which resulted in additional Form 483 observations that identified further areas for remediation / improvement We are implementing an aggressive remediation plan, including t

  106. Slide 106: Comprehensive MMS Product Review Underway

    15 Comprehensive MMS Product Review Underway Comprehensive, risk-based review of all MMS devices underway Complete device portfolio reviews to be completed by end of 2012 Initial reviews focused on Plum™, LifeCare PCA™ and GemStar™ Plum field remediation Expect field remediation to start in 2011 and

  107. Slide 107: Product and Process Remediation Timeline / Cost

    16 Product and Process Remediation Timeline / Cost One-time costs are expected to be ~70-75% of total costs Expected remediation timing: Expected cost impact: 2-3 years $200M-$250M

  108. Slide 108: Agenda

    17 17 17 Quality improvements Capacity to serve today Inventory as a patch Remediation update Investing in the future Agenda Summary

  109. Slide 109: Transforming Performance Through Our Operations Strategy

    18 18 Transforming the Performance of Our Business through Our Operations Strategy Best-in-class product quality and compliance Lowest total landed costs SKU reduction High customer service levels Responsive and flexible manufacturing assets Vision Key Elements Consistent execution, from concept thr

  110. Slide 110: Initiatives to Achieve the Vision

    19 19 We have Identified 10 Initiatives to Achieve the Vision Impact within 18 months Quick Strikes Long Burners Major impact within 18 months Increasing impact in 2-5 years Big Bangs Large impact in 3-5 years 5 3 Late-stage customization 7 Direct material reduction 1 Hospira performance system 6 SK

  111. Slide 111: India: Key Strategic Location for Hospira

    20 20 3 1 2 India will Serve as a Key Strategic Location for Hospira ZHOPL (JV) Ahmedabad Vizag Greenfield IKKT Chennai Cephalosporins, penicillins and carbapenem antibiotics R&D center of excellence Terminal sterilization and aseptic process manufacturing Significant capacity for future growth Cyto

  112. Slide 112: Significant Benefits to Operating in India

    21 21 Significant Benefits to Operating in India Remain a global cost leader in generic injectables Free up capacity in our US facilities to modernize and streamline operations without disrupting supply Compete more effectively in bid/tender markets Leverage experienced and successful team in Chenna

  113. Slide 113: Agenda

    22 22 22 Quality improvements Capacity to serve today Inventory as a patch Remediation update Investing in the future Agenda Summary

  114. Slide 114: In Summary: On Track to Deliver Operational Excellence

    23 23 IN SUMMARY We are On Track to Deliver Operational Excellence We are fixing our base and preparing the organization for supporting aggressive growth Quality improvement and remediation efforts will position us favorably for long term success We are investing in the future with strategic capacit

  115. Slide 115: Financial Strategy

    Financial Strategy Tom Werner, CFO

  116. Slide 116: Key Questions We Will Address Today

    2 2 2 Key Questions We Will Address Today How will our expansion initiatives be reflected in net sales and across product categories? Sales Gross margins R&D spend Working capital Capital allocation Can we still get to mid 40 percent adjusted margins? How will we drive expansion and how much comes f

  117. Slide 117: Agenda

    3 3 Agenda Sales, margins and earnings Capital allocation

  118. Slide 118: 2016 Financial Goals

    4 2016 Financial Goals 5-Year CAGR Mid to high single digits Low to mid teens Net Sales Earnings Per Share* * Earnings Per Share (EPS) is an adjusted; non-GAAP measure.

  119. Slide 119: Strong Sales Growth Outside US

    5 Strong Sales Growth Outside US 2011-2016 CAGR Mid single digits Low teens Low to mid teens Americas (includes US) EMEA APAC

  120. Slide 120: Accelerating Sales Growth

    6 Accelerating Sales Growth Sales growth accelerates in the latter years as key investments start to show returns 2012E 2013E 2014E 2015E 2016E 2011E Net Sales Mid single-digit growth Low teens growth

  121. Slide 121: Growth Driven by Key Strategic Areas

    7 Growth Driven by Key Strategic Areas 2016E 2011E SIP Contract Manufacturing Proprietary Pharma Solutions Biosimilars Medication Management Generic Injectables mid to high single digit 2011-2016 CAGR

  122. Slide 122: Opportunity to Expand Gross Margins

    8 Product Mix LEAN Cost Improvement 8 Further Opportunity to Expand Gross Margins 2011E 2016E Quality Improvement Costs Mid to upper 40% * Gross Margin is an adjusted; non-GAAP measure.

  123. Slide 123: Investing in R&D

    9 Investing in R&D R&D expense has historically run at approximately 6% of sales R&D profile will increase over the next couple of years to support investment in SIP portfolio expansion Expanding margins will allow for further longer-term R&D investments

  124. Slide 124: Flat SG&A Profile; Improved Mix

    10 Flat SG&A Profile; Improved Mix Sales & Marketing Sales & Marketing General & Administration General & Administration Investing in sales and marketing to support growth initiatives, such as biosimilars, while holding the line on G&A 2011E 2016E 14-15% of Sales

  125. Slide 125: Agenda

    11 11 Agenda Sales, margins and expenses Capital allocation

  126. Slide 126: Better Efficiency in Working Capital

    12 Better Efficiency in Working Capital Significant Improvement Driven by Improved Supply Chain Management and Centralized Purchasing DIOH * DIOH: Days Inventory on Hand. 2012E 2013E 2014E 2015E 2016E 2011E

  127. Slide 127: Investing Capital for Hospira's Future

    13 Investing Capital for Hospira’s Future R&D Manufacturing IT India Capacity Expansion New Products / Initiatives Pumps Capital Spending 2011-2016

  128. Slide 128: Poised to Generate Significant Cash Flows

    16 Poised to Generate Significant Cash Flows Cash Allocation 2011-2016E Debt Reduction Investments / Milestone Payments Targeted Cash Balance Committed to Share Repurchases Available for Repurchases, M&A Capital Expenditures $4-$5B

  129. Slide 129: Investing Today for Sustainable Long-Term Growth

    17 Investing Today for Sustainable Long-Term Growth The next 5 years is characterized by near-term investment We are investing to: capitalize on global revenue growth opportunity expand SIP manufacturing capacity to support future growth drive greater competitive advantage through enhancing our low-

  130. Slide 130: Current Small-Molecule Generic Portfolio by Therapeutic Area

    1 Hospira’s Current Small-Molecule Generic Portfolio by Therapeutic Area * LMV (local market value) refers to 2010 annual sales of equivalent products already being sold in the market. LMV is inclusive of the cumulative sales of all companies selling a product in a market where Hospira markets that

  131. Slide 131: Bridge of Previous to New Pipeline Reporting Methodology

    2 Bridge of Previous to New Pipeline Reporting Methodology The pipeline comparison uses the pipeline as reported for June 30, 2011. EU5 consists of France, Germany, Italy, Spain, UK; ANZ includes Australia. Previous Pipeline (molecules new to US, EU 5, AU) Additional Concept & Formulation Opportunit

Hospira — Investor Day (September 2011) on 6ix